Clinical features of patients in relation to the occurrence of aGVHD
| Clinical parameters . | Patients with aGVHD . | Patients without aGvHD . |
|---|---|---|
| No. patients | 24 | 10 |
| Median age, y (range) | 41 (22-52) | 41.5 (19-53) |
| Sex | ||
| Male | 12 | 6 |
| Female | 12 | 4 |
| GVHD grade | ||
| I | 23 | NA |
| II | 1 | NA |
| GVHD site | ||
| Mouth | 2 | NA |
| Skin | 16 | NA |
| Gut | 5 | NA |
| Liver | 1 | NA |
| Transplant donor | ||
| Sibling | 18 | 8 |
| MUD | 6 | 2 |
| Conditioning regimen | ||
| Myeloablative | 20 | 5 |
| Nonmyeloablative | 4 | 5 |
| Use of alemtuzumab | ||
| Yes | 9 | 6 |
| No | 18 | 4 |
| Clinical parameters . | Patients with aGVHD . | Patients without aGvHD . |
|---|---|---|
| No. patients | 24 | 10 |
| Median age, y (range) | 41 (22-52) | 41.5 (19-53) |
| Sex | ||
| Male | 12 | 6 |
| Female | 12 | 4 |
| GVHD grade | ||
| I | 23 | NA |
| II | 1 | NA |
| GVHD site | ||
| Mouth | 2 | NA |
| Skin | 16 | NA |
| Gut | 5 | NA |
| Liver | 1 | NA |
| Transplant donor | ||
| Sibling | 18 | 8 |
| MUD | 6 | 2 |
| Conditioning regimen | ||
| Myeloablative | 20 | 5 |
| Nonmyeloablative | 4 | 5 |
| Use of alemtuzumab | ||
| Yes | 9 | 6 |
| No | 18 | 4 |
Data are numbers of patients, except for median age.
NA indicates not applicable.